Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation

ABSTRACT

Afatinib exhibits therapeutic efficacy for lung adenocarcinoma patients harboring HER2 exon 20 insertions. HER2 S310Y single site substitution was discovered in recent years and afatinib efficacy for adenocarcinoma patients harboring S310Y mutation has not been reported. We presented a case of a 41-year-old male patient with lung adenocarcinoma harboring the HER2 S310Y mutation obtained clinical response to the treatment of afatinib, an oral HER family blocker. After the treatment of afatinib, the patient achieved partial response (PR) in chest lesions and almost complete response (CR) in intracranial lesions. He experienced progressive disease (PD) with liver metastasis and achieved a progression-free survival (PFS) of 5 months. He continually treated with afatinib after CT guided percutaneous radiofrequency ablation to eradicate the hepatic tumor cells and achieved stable disease (SD). In this study, we reported the first clinical evidence of efficacy generated by afatinib, the irreversible HER family inhibitor, targeting HER2 S310Y single site mutation in lung adenocarcinoma.

KEYWORDS:

• adenocarcinoma
• HER2 S310Y
• afatinib
• next-generation sequencing
• targeted therapy

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Informed consent statement

This study was approved by the Institutional Review Board at the Shenzhen People's Hospital. The patient provided informed consent and gave permission to this study.

Acknowledgments

The authors would like to thank Guangzhou Burning Rock for the next-generation sequencing.